Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2001

View Archived Issues

Tenofovir DF reaches primary efficacy endpoint in phase III trial

Licensing opportunity from NIH: anti-HIV benzoylalkylindolepyridinium compounds

NIH licensing opportunity: monoclonal antibodies specific for E2 glycoprotein of HCV

Available for licensing from NIH: cell-free assembly of lentiviral capsids

Pre- and postischemic renal protective effects described for Na+/Ca2+ exchange inhibitor

Nabi offers business development update

Abbott investigates antiinflammatory and antihyperalgesic effects of AK inhibitors

Effects of the herbal compound PC-SPES in androgen-independent prostate cancer

Beneficial effects of MEN-11467 on tachykininergic mucus secretion seen in ferret trachea

Quorex receives funding to develop novel antibacterial compounds

Potential antiulcer plant extracts discovered by Xechem

Idun licenses Bcl-2 gene to Selective Genetics

Otsuka presents new hypoglycemic phosphonic acid derivatives

Inhibitors of cell adhesion designed at Taisho

Statistically significant phase II results reported for INS-365 Ophthalmic

Selective inhibitors of alpha-fucosidase described by Japanese company for use in diabetes

Good tolerance and clinical efficacy of rhuIL-10 in Crohn's disease patients

Egis synthesizes new series of AMPA/kainate receptor antagonists

New muscarinic M3 receptor antagonists and therapeutic uses thereof

GSK studies new protein tyrosine kinase inhibitors particularly useful for cancer, psoriasis

Changes made to ViroPharma/Sanofi-Synthelabo pleconaril agreement

Chiesi regains European marketing rights to Curosurf

Specific inhibitor of PDE3 inhibits growth of tumor cells

Immune Network begins phase I trial in Canada of new Alzheimer's drug

Naturally occurring anti-HIV protein has potential as nonspermicidal vaginal microbicide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.